Fortress Biotech Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fortress Biotech Inc.
Zydus Lifesciences is building a rare disease-focused pipeline as a differentiating strategy, managing director Sharvil Patel tells Scrip in an interview. Innovation and patient centricity at heart, digital initiatives are being implemented to transform the company into a ‘future ready’ healthcare organization
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.
Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- Aevitas Therapeutics, Inc.
- Altamira Bio
- Avenue Therapeutics, Inc. (ATXI)
- Baergic Bio, Inc.
- Caelum Biosciences Inc.
- Cellvation, Inc.
- Checkpoint Therapeutics, Inc.
- Coronado Biosciences, Inc. (CNDO)
- Cyprium Therapeutics, Inc.
- DiaVax Biosciences
- Helocyte, Inc.
- Journey Medical Corporation (JMC)
- Mustang Bio, Inc.
- Mustang Therapeutics, Inc. (MBIO)
- National Holdings Corporation
- Oncogenuity, Inc.
- Tamid Bio, Inc.